SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-23-210724
Filing Date
2023-08-11
Accepted
2023-08-11 16:08:56
Documents
2
Group Members
JULIET TAMMENOMS BAKKERLONGITUDE PRIME FUND, L.P.LONGITUDE PRIME PARTNERS, LLCLONGITUDE VENTURE PARTNERS III, L.P.PATRICK G. ENRIGHT

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d528144dsc13da.htm SC 13D/A 118994
2 EX-99.4 d528144dex994.htm EX-99.4 7803
  Complete submission text file 0001193125-23-210724.txt   128598
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Subject) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91586 | Film No.: 231164129
SIC: 2834 Pharmaceutical Preparations

Mailing Address 800 EL CAMINO, SUITE 220 MENLO PARK CA 94025
Business Address 800 EL CAMINO, SUITE 220 MENLO PARK CA 94025 650-845-5700
Longitude Capital Partners III, LLC (Filed by) CIK: 0001713663 (see all company filings)

IRS No.: 811668051 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A